Cure Lab, Inc. today announced the award of a Phase I, two year small business biodefense grant from the National Institutes of Allergy and Infectious Diseases (NIAID). The overall size of the grant is $7 million.  Phase I budget released to Cure Lab, Inc. is in excess of $1 million. This grant aims at a feasibility study on Cure Lab’s technology for increased MHC-1 presentation of conserved influenza proteins, NP and M1. The ultimate goal of the project is the development of a vaccine product prototype.